454 related articles for article (PubMed ID: 31418588)
1. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
McCoy RG; Dykhoff HJ; Sangaralingham L; Ross JS; Karaca-Mandic P; Montori VM; Shah ND
Diabetes Technol Ther; 2019 Dec; 21(12):702-712. PubMed ID: 31418588
[No Abstract] [Full Text] [Related]
2. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
[TBL] [Abstract][Full Text] [Related]
3. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
Fu EL; Patorno E; Everett BM; Vaduganathan M; Solomon SD; Levin R; Schneeweiss S; Desai RJ
Eur Heart J; 2023 Jun; 44(24):2216-2230. PubMed ID: 37259575
[TBL] [Abstract][Full Text] [Related]
5. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
7. Sociodemographic disparities in sodium-glucose cotransporter-2 inhibitor use among US kidney transplant recipients: An observational study of real-world pharmacy records.
Lentine KL; Miyata KN; Lam NN; Joseph C; McAdams-DeMarco M; Bae S; Chen Y; Caliskan Y; Sarabu N; Dhindsa S; Xiao H; Segev DL; Axelrod DA; Schnitzler MA
Clin Transplant; 2024 Apr; 38(4):e15257. PubMed ID: 38563475
[TBL] [Abstract][Full Text] [Related]
8. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
[TBL] [Abstract][Full Text] [Related]
9. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
Ryan PB; Buse JB; Schuemie MJ; DeFalco F; Yuan Z; Stang PE; Berlin JA; Rosenthal N
Diabetes Obes Metab; 2018 Nov; 20(11):2585-2597. PubMed ID: 29938883
[TBL] [Abstract][Full Text] [Related]
11. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
[TBL] [Abstract][Full Text] [Related]
12. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
[TBL] [Abstract][Full Text] [Related]
13. Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.
Luo J; Feldman R; Rothenberger S; Korytkowski M; Fischer MA; Gellad WF
J Gen Intern Med; 2022 Nov; 37(14):3562-3569. PubMed ID: 35048301
[TBL] [Abstract][Full Text] [Related]
14. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
16. Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes.
McCoy RG; Lipska KJ; Van Houten HK; Shah ND
JAMA Netw Open; 2020 Jan; 3(1):e1919099. PubMed ID: 31922562
[TBL] [Abstract][Full Text] [Related]
17. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
18. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
19. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Suissa S
Diabetes Care; 2018 Jan; 41(1):6-10. PubMed ID: 29263192
[TBL] [Abstract][Full Text] [Related]
20. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
